Abstract

DAPAGLIFLOZIN: A DRUG REVIEW IN TYPE 2 DIABETES

Lalima Yadav, Bharti Shri, Faiqua Jamal, Salman Khan, Gyan Ranjan and Ishu*

.

Abstract

Hyperglycemia, which affects the heart, liver, skeletal muscle, and adipose tissue, is a hallmark of type 2 diabetes, a chronic, progressive disease. There were 382 million individuals worldwide diagnosed with diabetes in 2013, and the number is projected to reach 592 million by 2035, according to the most recent projections. A new family of drugs has emerged that complements insulin treatment by acting independently of insulin to block the kidney-based transporter protein sodium glucose co-transporter-2 (SGLT2). It is recently approved drug dapagliflozin (Forxiga) for the treatment of type 2 diabetes in the European Union. This insulin-dependent mechanism increases the rate of glucose excretion in urine. Dapagliflozin lowers blood glucose levels by a mechanism unrelated to insulin action by selectively and potently inhibiting SGLT2. Dapagliflozin did not show any pharmacokinetic interactions with metformin, pioglitazone, sitagliptin, or glimepiride that would be considered clinically relevant in healthy volunteers. The recommended dosage of dapagliflozin (10 mg/day) and had the same primary effectiveness outcome, the analyses the key findings of clinical trials using dapagliflozin in the management of type 2 diabetes. Dapagliflozin shows best result with type 2 diabetes mellitus and pre-existing cardiovascular disease or several risk factors for cardiovascular disease.

Keywords: SGLT-2 inhibitor, Dapagliflozin, type 2 diabetes, CVD.